Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

This study has been completed.
Information provided by:
AAADRS Clinical Research Center
ClinicalTrials.gov Identifier:
First received: August 28, 2007
Last updated: January 22, 2009
Last verified: January 2009
To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

Condition Intervention Phase
Drug: Nebulized Budesonide
Device: Nitric Oxide Analyzer
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase IV Study of the Effect of Nebulized Budesonide on Exhaled Nitric Oxide in Children, Four to Six Years of Age, With Asthma

Resource links provided by NLM:

Further study details as provided by AAADRS Clinical Research Center:

Primary Outcome Measures:
  • Exhaled breath nitric oxide pre- to post treatment [ Time Frame: two weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Spirometry with peak flow measurements and daily diary scores [ Time Frame: two weeks ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: August 2007
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Nebulized budesonide
Drug: Nebulized Budesonide
Pulmicort Respules 0.5mg/2cc
Other Name: Pulmicort Respules 0.5mg/2ml nebulized
Device: Nitric Oxide Analyzer
Niox NO analyzer
Other Name: Niox NO analyzer

Detailed Description:
Comparisons will be made before and after 2 week therapy of nebulized budesonide in children not on prior anti-inflammatory medications.

Ages Eligible for Study:   4 Years to 6 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Asthma diagnosis previously for 6 months
  • Past asthma medication without change for previous 6 months
  • Increased NO levels and ability to perform maneuver
  • ICF signed by parents

Exclusion Criteria:

  • Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks
  • Hospitalization within 3 months
  • Upper or lower airways active infection or cigarette smoke direct exposure
  • Use of other asthma medications other than bronchodilators one month prior and during the trial
  • Noncompliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00522782

United States, Florida
AAADRS Clinical Research Center
Coral Gables, Florida, United States, 33134
Sponsors and Collaborators
AAADRS Clinical Research Center
Principal Investigator: Miguel J Lanz, MD Principal Investigator
  More Information

Responsible Party: Miguel Lanz, MD, AAADRS
ClinicalTrials.gov Identifier: NCT00522782     History of Changes
Other Study ID Numbers: IRUSBUPR-0062 
Study First Received: August 28, 2007
Last Updated: January 22, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Nitric Oxide
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Endothelium-Dependent Relaxing Factors
Free Radical Scavengers
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on May 24, 2016